DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...
The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
GlobalData on MSN5d
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenueDexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...
Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last week citing issues at two of its manufacturing facilities. The warning ...
DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback